1. Home
  2. IMAB vs ASRT Comparison

IMAB vs ASRT Comparison

Compare IMAB & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • ASRT
  • Stock Information
  • Founded
  • IMAB 2014
  • ASRT 1995
  • Country
  • IMAB United States
  • ASRT United States
  • Employees
  • IMAB N/A
  • ASRT N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • ASRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMAB Health Care
  • ASRT Health Care
  • Exchange
  • IMAB Nasdaq
  • ASRT Nasdaq
  • Market Cap
  • IMAB 87.2M
  • ASRT 85.1M
  • IPO Year
  • IMAB 2020
  • ASRT 1997
  • Fundamental
  • Price
  • IMAB $0.99
  • ASRT $0.80
  • Analyst Decision
  • IMAB Strong Buy
  • ASRT Strong Buy
  • Analyst Count
  • IMAB 3
  • ASRT 4
  • Target Price
  • IMAB $8.00
  • ASRT $3.19
  • AVG Volume (30 Days)
  • IMAB 270.7K
  • ASRT 362.1K
  • Earning Date
  • IMAB 03-13-2025
  • ASRT 03-10-2025
  • Dividend Yield
  • IMAB N/A
  • ASRT N/A
  • EPS Growth
  • IMAB N/A
  • ASRT N/A
  • EPS
  • IMAB N/A
  • ASRT N/A
  • Revenue
  • IMAB $3,313,984.00
  • ASRT $125,763,000.00
  • Revenue This Year
  • IMAB N/A
  • ASRT N/A
  • Revenue Next Year
  • IMAB N/A
  • ASRT $1.84
  • P/E Ratio
  • IMAB N/A
  • ASRT N/A
  • Revenue Growth
  • IMAB N/A
  • ASRT N/A
  • 52 Week Low
  • IMAB $0.84
  • ASRT $0.73
  • 52 Week High
  • IMAB $2.00
  • ASRT $1.80
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • ASRT 43.92
  • Support Level
  • IMAB $1.03
  • ASRT $0.78
  • Resistance Level
  • IMAB $1.10
  • ASRT $0.83
  • Average True Range (ATR)
  • IMAB 0.06
  • ASRT 0.03
  • MACD
  • IMAB -0.01
  • ASRT 0.00
  • Stochastic Oscillator
  • IMAB 7.58
  • ASRT 39.86

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: